(NASDAQ:SCNI) JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases...
Related Questions
How does the reported CDMO revenue growth compare to market expectations and previous quarters?
What does the strengthened balance sheet mean for cash runway and potential future R&D or acquisition spending?
Did management provide guidance on upcoming milestones, product launches, or regulatory events that could affect the stock's volatility?